{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:52:14Z","timestamp":1762876334439,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.arteri.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T01:47:16Z","timestamp":1634262436000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Situaci\u00f3n en 2020 de los requerimientos para la utilizaci\u00f3n de inhibidores de PCSK9 en Espa\u00f1a: resultados de una encuesta nacional"],"prefix":"10.1016","volume":"34","author":[{"given":"Carlos","family":"Guijarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Masana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Valdivielso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"[Internet].","article-title":"Cardiovascular diseases","year":"2020","key":"10.1016\/j.arteri.2021.07.002_bib0100"},{"journal-title":"[Internet].","article-title":"Defunciones por causas (lista reducida) por sexo y grupos de edad","year":"2021","key":"10.1016\/j.arteri.2021.07.002_bib0105"},{"journal-title":"Defunciones seg\u00fan la causa de muerte","year":"2018","key":"10.1016\/j.arteri.2021.07.002_bib0110"},{"key":"10.1016\/j.arteri.2021.07.002_bib0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2021.07.002_bib0120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2021.07.002_bib0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.arteri.2021.07.002_bib0130","first-page":"341","article-title":"Inhibidores de proprote\u00edna convertasa subtilisina\/kexina tipo 9 (iPCSK9). Los nuevos de la clase en el tratamiento de la hipercolesterolemia","volume":"64","author":"Ortega Mart\u00ednez de Victoria","year":"2020","journal-title":"Endocrinol Diabetes."},{"key":"10.1016\/j.arteri.2021.07.002_bib0135","first-page":"128","article-title":"Indications of PCSK9 inhibitors in clinical practice Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2021.07.002_bib0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cpt.281","article-title":"Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids","volume":"99","author":"Shantha","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.arteri.2021.07.002_bib0145","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/1060028018771670","article-title":"The role of PCSK9 inhibitors in the treatment of hypercholesterolemia","volume":"52","author":"Patel","year":"2018","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.arteri.2021.07.002_bib0150","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia [publicado 3 Mar 2016] [consultado Nov 2020]. Disponible en: http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-evolocumab-repatha.pdf"},{"key":"10.1016\/j.arteri.2021.07.002_bib0155","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de alirocumab (Praluent\u00ae) en hipercolesterolemia [publicado 22 Abr 2016]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-alirocumab-Praluent-hipercolesterolemia.pdf"},{"key":"10.1016\/j.arteri.2021.07.002_bib0160","first-page":"164","article-title":"Documento de consenso de la Sociedad Espa\u00f1ola de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9","volume":"28","author":"Masana","year":"2016","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2021.07.002_bib0165","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: A quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2021.07.002_bib0170","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.07.002_bib0175","unstructured":"Committee for Medicinal Products for Human Use. Assessment report: Repatha [publicado 22 Feb 2018] [consultado Nov 2020]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/repatha-h-c-3766-ii-0017-g-epar-assessment-report-variation_en.pdf"},{"key":"10.1016\/j.arteri.2021.07.002_bib0180","unstructured":"Committee for Medicinal Products for Human Use. Assessment report: Praluent 31 january 2019, [consultado 30 Jun 2021]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-praluent-ii-42_en.pdf"},{"key":"10.1016\/j.arteri.2021.07.002_bib0185","unstructured":"Sanitarios AEdMyP. Informe de posicionamiento terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia. 21 de octubre del 2020. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios."},{"key":"10.1016\/j.arteri.2021.07.002_bib0190","unstructured":"sanitarios AEdmyp. Informe de posicionamiento terap\u00e9utico de alirocumab (Praluent\u00ae) en hipercolesterolemia, 21 de octubre del 2020; [consultado 30 Jun 2021]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_13-2020-alirocumab-Praluent.pdf?x53593"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:55Z","timestamp":1759325575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0214916821001297"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.07.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Situaci\u00f3n en 2020 de los requerimientos para la utilizaci\u00f3n de inhibidores de PCSK9 en Espa\u00f1a: resultados de una encuesta nacional","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}]}}